NCT01924520已完成1 期
Phase I Study of FK949E - Phase I Oral Multiple-dose Study in Patients With Major Depressive Disorder
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 主要终点
- Maximum plasma concentration (Cmax) of unchanged quetiapine
研究概览
简要总结
A study was to evaluate the safety and plasma concentration changes of quetiapine after repeated administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive disorder (MDD).
详细描述
The objective of the study was to evaluate the safety and pharmacokinetics of multiple oral doses of FK949E (extended-release formulation of quetiapine) of three doses in patients with major depressive disorder (MDD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of major depressive disorder by the M.I.N.I. according to the DSM-IV-TR
- •Female patients of childbearing potential with a negative serum pregnancy test result and who were willing and able to use a reliable method of birth control during the study.
- •Patients who could understand and comply with the requirements of the study, as judged by the investigator/sub-investigator.
排除标准
- •A current or past history of a DSM-IV-TR Axis I disorder other than major depressive disorder within 6 months prior to provision of written informed consent.
- •Diagnosis of a DSM-IV-TR Axis II disorder that was considered to have a major impact on the patient's current psychiatric status.
- •A history of substance or alcohol abuse or dependence excluding caffeine and nicotine.
- •Patients who were unable to abstain from drugs that induce or inhibit the drug-metabolizing enzyme CYP3A4 from 14 days prior to screening assessment and throughout the study period.
- •Patients showing evidence or signs of renal or hepatic failure, serious heart disease, cerebrovascular disease, viral hepatitis B or C, or acquired immunodeficiency syndrome (AIDS) (carrier).
- •Patients being treated for hypertension or patients with clinical finding that in the opinion of the investigator/sub-investigator could be negatively affected by the study or that would affect the study results (e.g., hypertension, unstable angina).
- •Patients with concomitant hypotension or orthostatic hypotension (hypotension is defined as systolic blood pressure of less than 100 mmHg)
- •Conditions that could affect absorption and metabolism of the study medication (e.g., malabsorption syndrome, liver disease)
- •A current diagnosis of malignant tumor unless in remission for at least 5 years (except basal or squamous cell skin carcinoma).
- •A history of transient ischemic attack (TIA).
- •A history of seizure disorder, except for febrile convulsions
- •Application of electroconvulsive therapy within 90 days prior to the start of study drug administration
- •Use of a depot antipsychotic injection and inability to be off the drug for a period of twice the dosing interval prior to screening assessment and throughout the study period
- •A score of ≥ 3 on the HAM-D17 Item (suicide) or a suicide attempt within the past 6 months. Patients judged to be at serious suicidal or homicidal risk in the opinion of the investigator/sub-investigator.
研究组 & 干预措施
Group 1 (FK949E lower dose)
Experimental
Oral
干预措施: FK949E (Drug)
Group 2 (FK949E middle dose)
Experimental
Oral
干预措施: FK949E (Drug)
Group 3 (FK949E higher dose)
Experimental
Oral
干预措施: FK949E (Drug)
结局指标
主要结局
Maximum plasma concentration (Cmax) of unchanged quetiapine
时间窗: for 24 hours after dosing
AUC24h (area under the curve for 24hr) of unchanged quetiapine
时间窗: for 24 hours after dosing
次要结局
- t1/2 of plasma concentration of unchanged quetiapine(for 24 hours after dosing)
- Maximum plasma concentration (Cmax) of quetiapine metabolites(for 24 hours after dosing)
- trough value of plasma concentration of unchanged quetiapine(for 24 hours after dosing)
- AUC (area under the curve) of quetiapine metabolites(for 24 hours after dosing)
- trough value of plasma concentration of quetiapine metabolites(for 24 hours after dosing)
- tmax of plasma concentration of quetiapine metabolites(for 24 hours after dosing)
- t1/2 of plasma concentration of quetiapine metabolites(for 24 hours after dosing)
- Safety assessed by the incidence of adverse events, clinical tab tests, vital signs, 12-lead ECGs and physical exam(Up to Day 14)
研究者
相似试验
已完成
1 期
Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive DisorderMajor Depressive Disorder PatientsNCT01871974Astellas Pharma Inc16
已完成
1 期
Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive DisorderMajor Depressive Disorder PatientsNCT01903200Astellas Pharma Inc16
已完成
3 期
Phase III/Seroquel SR Bipolar Depression Monotherapy - USAffective Psychosis, BipolarDepression, BipolarManic-Depressive PsychosisPsychoses, Manic-DepressiveNCT00422214AstraZeneca400
已完成
3 期
Phase 3 /Seroquel SR Acute Mania Monotherapy - USAffective Psychosis, BipolarManic DisorderManic-Depressive PsychosisManic StatePsychoses, Manic-DepressiveManiaNCT00422123AstraZeneca447
已完成
1 期
Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male VolunteersHealthyPharmacokinetics of QuetiapineNCT01908296Astellas Pharma Inc24